I care more about the recursive loop between execution and cost. Anything that executes - be it biological or artificial - incurs some costs. Those costs in turn impact what execution can follow. The gains pay for action, action produces gains.

LLMs are also expensive, not platonic executions. We talk all day long about their costs. Companies developing them are looped with users, investors, competitors and hardware producers. There is a lineage. The self-reference Aaronson can't find in the architecture is in the bill.